QQQ   444.26 (-0.13%)
AAPL   171.22 (-1.21%)
MSFT   419.90 (-0.36%)
META   485.80 (-1.63%)
GOOGL   150.63 (-0.16%)
AMZN   180.13 (+0.17%)
TSLA   177.49 (-1.30%)
NVDA   905.75 (+0.36%)
NIO   4.58 (-1.93%)
AMD   181.20 (+0.90%)
BABA   72.46 (+1.22%)
T   17.63 (+0.46%)
F   13.19 (+1.00%)
MU   117.87 (-1.07%)
CGC   9.90 (+3.66%)
GE   175.20 (-2.73%)
DIS   122.59 (+1.33%)
AMC   3.67 (-15.44%)
PFE   27.99 (+0.76%)
PYPL   67.23 (+0.99%)
XOM   115.69 (+0.63%)
QQQ   444.26 (-0.13%)
AAPL   171.22 (-1.21%)
MSFT   419.90 (-0.36%)
META   485.80 (-1.63%)
GOOGL   150.63 (-0.16%)
AMZN   180.13 (+0.17%)
TSLA   177.49 (-1.30%)
NVDA   905.75 (+0.36%)
NIO   4.58 (-1.93%)
AMD   181.20 (+0.90%)
BABA   72.46 (+1.22%)
T   17.63 (+0.46%)
F   13.19 (+1.00%)
MU   117.87 (-1.07%)
CGC   9.90 (+3.66%)
GE   175.20 (-2.73%)
DIS   122.59 (+1.33%)
AMC   3.67 (-15.44%)
PFE   27.99 (+0.76%)
PYPL   67.23 (+0.99%)
XOM   115.69 (+0.63%)
QQQ   444.26 (-0.13%)
AAPL   171.22 (-1.21%)
MSFT   419.90 (-0.36%)
META   485.80 (-1.63%)
GOOGL   150.63 (-0.16%)
AMZN   180.13 (+0.17%)
TSLA   177.49 (-1.30%)
NVDA   905.75 (+0.36%)
NIO   4.58 (-1.93%)
AMD   181.20 (+0.90%)
BABA   72.46 (+1.22%)
T   17.63 (+0.46%)
F   13.19 (+1.00%)
MU   117.87 (-1.07%)
CGC   9.90 (+3.66%)
GE   175.20 (-2.73%)
DIS   122.59 (+1.33%)
AMC   3.67 (-15.44%)
PFE   27.99 (+0.76%)
PYPL   67.23 (+0.99%)
XOM   115.69 (+0.63%)
QQQ   444.26 (-0.13%)
AAPL   171.22 (-1.21%)
MSFT   419.90 (-0.36%)
META   485.80 (-1.63%)
GOOGL   150.63 (-0.16%)
AMZN   180.13 (+0.17%)
TSLA   177.49 (-1.30%)
NVDA   905.75 (+0.36%)
NIO   4.58 (-1.93%)
AMD   181.20 (+0.90%)
BABA   72.46 (+1.22%)
T   17.63 (+0.46%)
F   13.19 (+1.00%)
MU   117.87 (-1.07%)
CGC   9.90 (+3.66%)
GE   175.20 (-2.73%)
DIS   122.59 (+1.33%)
AMC   3.67 (-15.44%)
PFE   27.99 (+0.76%)
PYPL   67.23 (+0.99%)
XOM   115.69 (+0.63%)
LON:TRX

Tissue Regenix Group (TRX) Share Price, News & Analysis

GBX 63
0.00 (0.00%)
(As of 03:40 PM ET)
Today's Range
62
63
50-Day Range
50
72.94
52-Week Range
48
72.94
Volume
2,827 shs
Average Volume
65,530 shs
Market Capitalization
£44.46 million
P/E Ratio
N/A
Dividend Yield
4.12%
Price Target
N/A
TRX stock logo

About Tissue Regenix Group Stock (LON:TRX)

Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of bone graft substitutes and soft tissue in the United States and internationally. It operates in three segments: dCELL, BioRinse, and GBM-V. The company provides dCELL technology, a soft tissue decellularisation process that removes DNA and other cellular material from animal and human soft tissue to repair diseased or damaged body parts; and BioRinse technology, a natural bone filler solution for osteoinductivity to stimulate and regenerate native bone growth. It also offers DermaPure, a decellularised dermal allograft for reinforcement, repair, and replacement of damaged or inadequate integumental tissue and other homologous uses of human integument; and SurgiPure XD, a decellularised porcine dermal reconstructive tissue matrix for the repair of hernias and body wall defects. In addition, it provides OrthoPure XT, a scaffold to replace the damaged tissue that will re-populate with the patient's own cells; ConCelltrate 100, a verified osteoinductive bone matrix; MatrixCellect 100, a demineralised bone matrix (DBM) for orthopaedic; Matrix IQ Dermis, a human-derived dermal graft, which is decellularised to remove cellular components and preserve the biological properties that promote revascularisation, repair, and augmentation of damaged tissue; and Matrix OI FlexIt, a thin pliable demineralised cortical allograft bone sheet. Further, the company offers DentalFix, a mineralized particulate allograft that offer osteoconductive properties of natural bone; Matrix OI 100 DBM for non-structural bone-grafting; Matrix OI Strips and Blocks, a stem cell containment human scaffold; AmnioWorks to optimise membrane defects; and sports medicine products. The company was incorporated in 2006 and is based in Garforth, the United Kingdom.

TRX Stock Price History

TRX Stock News Headlines

Tissue Regenix Group Share Chat
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Tissue Regenix Group PLC TRX
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Tissue by Imtiaz Dharker
When Will Tissue Regenix Group plc (LON:TRX) Breakeven?
Tissue Regenix inks German distribution deal
See More Headlines
Receive TRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tissue Regenix Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
9/02/2020
Today
3/28/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
82
Year Founded
N/A

Profitability

Net Income
£-1,980,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£26.74 million
Cash Flow
GBX 11.05 per share
Book Value
GBX 44 per share

Miscellaneous

Free Float
N/A
Market Cap
£44.46 million
Optionable
Not Optionable
Beta
1.48
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Daniel Ray Lee (Age 63)
    CEO & Director
    Comp: $492.86k
  • Mr. David Claiborne Cocke (Age 59)
    CFO & Executive Director
    Comp: $291.27k
  • Ms. Christine Rowley
    Technical & Operations Director - UK
  • Tina Trimble
    Senior Vice President, Donor Services - U.S.
  • Ms. Kirsten Mary Lund
    EMEA Business Director & Company Secretary

TRX Stock Analysis - Frequently Asked Questions

How have TRX shares performed in 2024?

Tissue Regenix Group's stock was trading at GBX 52 at the beginning of 2024. Since then, TRX shares have increased by 21.2% and is now trading at GBX 63.
View the best growth stocks for 2024 here
.

How were Tissue Regenix Group's earnings last quarter?

Tissue Regenix Group plc (LON:TRX) posted its earnings results on Wednesday, September, 2nd. The company reported ($0.16) earnings per share (EPS) for the quarter. Tissue Regenix Group had a negative trailing twelve-month return on equity of 6.15% and a negative net margin of 7.42%.

What other stocks do shareholders of Tissue Regenix Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tissue Regenix Group investors own include Argos Therapeutics (ARGSQ), Swedbank AB (publ) (SWDBY), Trevena (TRVN), Allied Minds (ALM), ArQule (ARQL), Boeing (BA), CIRCOR International (CIR), WisdomTree Middle East Dividend Fund (GULF) and W.W. Grainger (GWW).

How do I buy shares of Tissue Regenix Group?

Shares of TRX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:TRX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners